The James A. Rand Young Investigator's Award: What Is the Safest and Most Effective Dose of Intravenous Dexamethasone in Total Knee Arthroplasty? A Multicenter Randomized Controlled Trial.

この研究はインパクトが大きい可能性があると判断されました。 OEのAIによるハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文の影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することができ、読者は将来の診療を形成する可能性が最も高い論文に焦点を当てることができます。

研究概要

Four hundred and thirty eight patients undergoing inpatient primary TKA at 11 centers were randomized to receive 4 mg (n = 146), 8 mg (n = 147), or 16 mg (n = 145) of intraoperative IV dexamethasone, all within an identical multimodal analgesia/anesthesia protocol including neuraxial anesthesia, adductor canal block, periarticular injection, and standardized oral analgesics. The primary outcome was cumulative opioid consumption in oral morphine milligram equivalents (MME) over the first 48 hours postoperatively. Secondary outcomes included daily opioid use to 7 days, pain at rest and with activity, nausea scores, vomiting episodes, sleep duration, postoperative day 1 (POD1) glucose, length of stay, and 90-day complications. Outcomes were assessed with a 7-day patient diary and chart review through 90 days. Overall, the results of the study revealed that 16 mg IV dexamethasone modestly reduced early opioid consumption (particularly vs 8 mg), improved pain at rest and reduced vomiting within 24 hours, but increased POD1 glucose in a dose-dependent fashion without increasing short-term complication rates. These findings suggest that 16 mg may be the most efficacious dose for early postoperative comfort in otherwise well-controlled patients, while lower doses may be preferable in patients at higher risk from hyperglycemia.